Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancerManuela Milani, Giandomenico Roviello, Simone Bonardi et al.|Oncotarget|2017Cited by 12
Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of LiteratureOttavia Bernocchi, Daniele Generali, Marianna Sirico et al.|Pharmaceuticals|2021Cited by 12
A Phase II Study of Olaparib in Breast Cancer Patients: Biological Evaluation from a ‘Window of Opportunity’ TrialGiandomenico Roviello, Daniele Generali, Manuela Milani et al.|Future Oncology|2016Cited by 10
A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-Negative Breast CancersGiandomenico Roviello, Daniele Generali, Manuela Milani et al.|Clinical Breast Cancer|2016Cited by 7
Could gonadotropin-releasing hormone analogs be helpful in the treatment of triple-negative breast cancer?Silvia Paola Corona, Daniele Generali, Giandomenico Roviello et al.|Future Oncology|2017Cited by 6